LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA)

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

LIRICA is a prospective non-randomized study aimed at exploring the outcome of liver transplantation in selected patients with unresectable iCCA after a downstaging/disease control protocol with standard of care chemotherapy, in terms of overall survival and quality of life. Additionally, the study aims to identify pre-transplant biological markers and clinical factors that can stratify patients with the best post-transplant prognosis. Finally, the study aims to investigate the role of preoperative PET-MR, especially in relation to lymph node locations, by correlating the results with histological examination after iliac lymphadenectomy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Histologically confirmed diagnosis of iCCA

• First diagnosis of iCCA

• Recurrence after R0 hepatic resection, N0, M0 without macrovascular invasion

• Disease considered unsuitable for hepatic resection based on tumor location and extent or underlying liver dysfunction

• Absence of major vascular invasion, extrahepatic disease, or involvement of regional lymph nodes detected on radiological study

• No evidence of extrahepatic metastatic disease after chest-abdomen-pelvis CT and PET-MR (or PET-CT)

• At least six months have passed since the first diagnosis of iCCA (or recurrence) to the date of inclusion on the liver transplant waiting list

• The patient has received at least six months of SOC chemotherapy, achieving disease stability or partial response (according to RECIST version 1.1) at the time of listing for transplantation

• Hematochemical evaluation: Hb ≥ 9 g/dL, Leukocytes ≥ 3.0 X 109/L, Neutrophils ≥ 1.5 X 109/L, Platelets ≥ 100,000/mm3 (≥ 10 X 109/L), Total Bilirubin ≤ 3 mg/dL (≤ 51 umol/L), AST or ALT ≤ 5 times the upper limit of normal, Serum Creatinine and Urea \< 1.5 times the upper limit of normal

• ECOG (Eastern Cooperative Oncology Group) performance status ≤ 1

• Patient's BMI ≥ 18 and ≤ 30 kg/m2

• Signed informed consent, and expected patient cooperation for treatment and follow-up, must be obtained and documented according to good clinical practice and national/local regulations

Locations
Other Locations
Italy
Azienda Ospedale Università di Padova
RECRUITING
Padua
Contact Information
Primary
Enrico Gringeri, Prof.
enrico.gringeri@unipd.it
+39 0498218547
Time Frame
Start Date: 2024-01-15
Estimated Completion Date: 2033-11-01
Participants
Target number of participants: 10
Treatments
Experimental: Study population
Candidates will be evaluated by theMultidisciplinary Group after routine radiological studies (CT, MRI, PET-MR/CT).~Patients will receive 6 months of standard of care chemotherapy and undergo PET-MR with FDG to exclude the presence of extrahepatic disease.~Following completion of therapy, patients will undergo radiological restaging. If the disease is resectable, the patient will be considered for curative-intent surgical resection; if not, the patients will be evaluated by the Center's Multidisciplinary Transplantation Group.~Patients will continue chemotherapy until a compatible liver becomes available. If there are no further contraindications, exploratory laparotomy and surgical nodal staging of the tumor will be performed at the time of transplantation. If there are no signs of extrahepatic disease, transplantation will be conducted according to institutional protocols.
Sponsors
Collaborators: Istituto Oncologico Veneto IRCCS
Leads: Azienda Sanitaria Ospedaliera

This content was sourced from clinicaltrials.gov